enVVeno Medical Corporation (NVNO)
NASDAQ: NVNO · Real-Time Price · USD
4.550
-0.030 (-0.66%)
Aug 14, 2025, 9:03 AM - Market open
enVVeno Medical Employees
enVVeno Medical had 37 employees as of December 31, 2024. The number of employees increased by 6 or 19.35% compared to the previous year.
Employees
37
Change (1Y)
6
Growth (1Y)
19.35%
Revenue / Employee
n/a
Profits / Employee
-$623,459
Market Cap
87.57M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NVNO News
- 8 days ago - Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency - Accesswire
- 10 days ago - enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company - Accesswire
- 13 days ago - enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Accesswire
- 23 days ago - enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference - Accesswire
- 2 months ago - Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting - Accesswire
- 3 months ago - enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer - Accesswire
- 3 months ago - Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery - Accesswire
- 3 months ago - enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24 - Accesswire